Study title:
Alberto Broniscer, Suzanne J. Baker, Clinton F. Stewart, Thomas E. Merchant, Fred H.Laningham, Paula Schaiquevich, Mehmet Kocak, E. Brannon Morris, Raelene Endersby, David W. Ellison, Amar Gajjar
January 2009 (Abstract at ASCO 2007)Clin. Cancer Research; Phase I and Pharmacokinetics studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade glioma; 15(2): 701-707 PMID: 19147777 [PubMed - indexed for MEDLINE]
Type of medicine: Centrally authorised medicines
|
Therapeutic area: Neoplasms
|
Brands: Please see report, Please see report, Please see report, Please see report, Please see report |
MAH holders: Please see report, Please see report |
Assessment: |
Active substance: erlotinib |
ATC code: L01XX34 |
Document link:
|
Document date:
|
Study number: |
EudraCT number:
|
Scope of study: CLINICAL |
Population of study subjects:
|
Preterm newborn Infants
|
Newborn infants
(1 to 27 days)
|
Infants and toddlers
(28 days to 24 months)
|
Children
(2 to 11 years)
|
Adolescents
(12 to 18 years)
|
|
-
|
-
|
-
|
-
|
-
|